- Revenue from primary healthcare business remained resilient with a drop of 7.3% despite massive lock-downs in China in 2022 - Excluding non-cash impairment loss on investment in associate, loss after
CATALIST-listed AOXIN Q&M reports lower revenue of RMB 140m for full year ended 31 December 2022 jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.
acnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from acnnewswire.com Daily Mail and Mail on Sunday newspapers.
CATALIST-listed AOXIN Q&M records 21% growth in revenue for full year ended 31 December 2021 jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.
- EBITDA grew 47% for 12 months ended 31 Dec 2021- Proposed listing of 49%-owned Acumen Diagnostics on NASDAQ will enhance AOXIN's shareholder value- Growth trend in revenue expected to continue as COVID-19